Common Questions About AAV Gene Therapy and Viral Vector Design
Adeno-associated virus (AAV) has emerged as the dominant delivery platform for in vivo gene therapy, with approved products targeting conditions from spinal muscular atrophy to hemophilia B to inherited retinal dystrophy. Despite this progress, developers and clinicians new to the field frequently encounter the same set of foundational questions. This article addresses the most common ones directly.
Which AAV Serotype Should I Use for My Target Tissue?
AAV serotype selection is one of the most consequential early decisions in a gene therapy program. Serotypes differ in their surface capsid proteins, which determine which cell surface receptors they bind and therefore which tissues they infect preferentially. AAV9 and AAVrh10 are highly efficient in the central nervous system and cross the blood-brain barrier when delivered systemically, making them the vectors of choice for neurological indications. AAV8 and AAV3B demonstrate superior liver transduction. AAV2 and AAV5 have established track records in retinal gene therapy. AAV1 and AAV6 are efficient in skeletal muscle. For novel indications, capsid engineering approaches including directed evolution and rational design are generating next-generation variants with improved potency, tissue selectivity, and reduced immunogenicity compared to natural serotypes.
What Are the Key Manufacturing Challenges for AAV at Scale?
Manufacturing remains one of the largest bottlenecks in bringing AAV gene therapies to market. Clinical and commercial production requires generating virus at scales orders of magnitude larger than research quantities, while maintaining consistent quality, purity, and potency. The two dominant production platforms are HEK293-based transient transfection using triple-plasmid systems and baculovirus-insect cell (Sf9) systems. Each has trade-offs in yield, cost, scalability, and the ratio of full (genome-containing) to empty capsids produced. Downstream purification — typically involving cesium chloride ultracentrifugation or affinity chromatography followed by ion exchange polishing — must achieve high full-capsid enrichment since empty capsids can contribute to immunogenicity without delivering therapeutic payload.
How Is AAV Dose Determined?
AAV dose is expressed as vector genomes (vg) per kilogram of body weight, or as total vg for fixed-dose regimens. Determining the therapeutic window — the range between the minimum effective dose and the maximum tolerated dose — requires extensive preclinical work in relevant animal models. Dose scales poorly from rodents to non-human primates to humans due to differences in body mass, immune reactivity, and target tissue volume. Pediatric dosing is particularly complex because as patients grow, the dilution of non-replicating vector across a larger cell mass may reduce efficacy over time, a concern driving interest in redosable platforms and self-complementary AAV designs. Phase I clinical trials use dose-escalation designs to establish safety and preliminary efficacy in humans.
Can Patients Receive AAV Gene Therapy More Than Once?
Re-administration of AAV is complicated by the neutralizing antibodies generated after the first dose. These antibodies rapidly neutralize a second dose of the same serotype, preventing effective transduction. This is a significant limitation for therapies where the initial dose proves insufficient or where the therapeutic effect wanes over time. Approaches under development to enable redosing include: using different serotypes for sequential administrations (serotype switching), transient immunosuppression around the time of dosing, plasmapheresis to reduce antibody titers prior to redosing, and non-viral delivery systems for subsequent administrations. Several research programs are also developing capsid variants that evade pre-existing neutralizing antibodies from natural AAV exposure.
GeneConversions provides end-to-end support for viral vector design and AAV-based therapy development. Visit our homepage to explore our platform capabilities, or reach out to our team with specific development questions.